Vice President Harris's urgent call to the DEA to expedite the rescheduling of cannabis marks a crucial turning point in national drug policy, as analyzed in a comprehensive equity research report by Zuanic & Associates.

The report delves into the implications of Harris's push as well as the Department of Health and Human Services' (HHS) engagement with the Justice Department's Office of Legal Counsel on the complexities of altering cannabis's legal status.

In addition, senior analyst Pablo Zuanic addresses critical industry questions, covering FDA oversight, prescription criteria, insurance reimbursement, and the effects of legalization and rescheduling...